Avicanna Reports Q3 2025

Core Insights - Avicanna Inc. reported Q3 2025 results, highlighting continued revenue growth and advancements in its biopharmaceutical strategy focused on cannabinoid-based products [1][2]. Financial Performance - Revenue for Q3 2025 reached $6.40 million, with a total of $18.88 million for the nine-month period ending September 30, 2025. Canadian revenue increased by 4%, marking two consecutive quarters of growth, while international revenue rose by approximately 6% compared to Q2 2025 [5]. - Gross profit was $3.15 million for Q3 2025, resulting in a gross margin of 49%, down from 57% in the prior year due to non-recurring costs and a Canada Post strike. The nine-month gross margin improved slightly to 52% from 50% in the previous period [5]. - The adjusted EBITDA loss for Q3 2025 was $0.79 million, a decrease from the same period in 2024, while the nine-month adjusted EBITDA loss was $0.61 million, showing improvement from $0.72 million in 2024 [5]. Commercial Advancements - Canadian commercial advancements led to record sales of 62,987 units in Q3 2025, a 39% increase compared to Q3 2024. The company had 52 commercial SKUs and 174 listings, representing 29% growth from Q3 2024 and 18% growth from Q2 2025 [5]. - The MyMedi.ca platform experienced growth due to medical affairs initiatives, and the B2B Medical unit saw a 113% increase in products sold. The Adult-Use business expanded into three new provinces and territories [5]. Intellectual Property and Collaborations - The United States Patent & Trademark Office issued patent No. US 12,343,315 B2 for a topical gel formulation containing cannabinoids, aimed at treating skin conditions such as acne and wrinkles [5]. - Avicanna's subsidiary completed the export of CBD-dominant cannabis flower to Switzerland, marking the first export of organic certified flower and expanding the Aureus portfolio in international markets [5]. New Product Launches - Avicanna LATAM SAS and Harrington Wellness launched the re+PLAY CBD wellness brand in the U.S., featuring products that utilize Avicanna's patented CBD formulations [6].